Wegovy : This is another once-weekly injection, but it is specifically approved for weight management
They are being investigated for a wide range of diseases, including cancer [4], metabolic disorders [5], autoimmune conditions [6], and wound healing [7, 8]
(2012) demonstrated: Statistically significant reductions in visceral adipose tissue of approximately 1518% over 26 weeks compared to placebo Meaningful increases in IGF-1 levels Improvements in triglyceride profiles in some patient subgroups Effects were partially reversed upon discontinuation, suggesting that sustained benefit requires ongoing therapy The consistency of the VAT reduction finding across multiple trials is what anchors tesamorelin's clinical utility
The decision must be made by reviewing the persons overall health, symptoms, and goals of treatment
As of mid-2026, the published literature contains over 212 peer-reviewed studies examining BPC-157 across virtually every organ and tissue system musculoskeletal healing, gastrointestinal protection, neurological function, wound repair, inflammatory modulation, angiogenesis, cardiovascular research and more
